Bio-Rad Laboratories Inc
$ 268.70
0.17%
24 Feb - close price
- Market Cap 7,240,173,000 USD
- Current Price $ 268.70
- High / Low $ 275.99 / 267.82
- Stock P/E 9.64
- Book Value 276.16
- EPS 27.84
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.11 %
- 52 Week High 343.12
- 52 Week Low 211.43
About
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Analyst Target Price
$324.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-15 | 2023-10-26 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 2.51 | 2.26 | 2.61 | 2.54 | 2.9 | 2.01 | 3.11 | 2.29 | 3.1 | 2.33 | 3 | 3.34 |
| Estimated EPS | 2.71 | 1.94 | 1.75 | 1.78 | 2.88 | 1.18 | 2.01 | 2.15 | 2.82 | 2.78 | 2.68 | 3.54 |
| Surprise | -0.2 | 0.32 | 0.86 | 0.76 | 0.02 | 0.83 | 1.1 | 0.14 | 0.28 | -0.45 | 0.32 | -0.2 |
| Surprise Percentage | -7.3801% | 16.4948% | 49.1429% | 42.6966% | 0.6944% | 70.339% | 54.7264% | 6.5116% | 9.9291% | -16.1871% | 11.9403% | -5.6497% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.55 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO
2026-02-23 05:08:52
Lake Forest College's Biochemistry and Molecular Biology department provides a comprehensive list of its available equipment and facilities. The resources range from nucleic acid preparation and analysis tools like gradient thermal cyclers and quantitative PCR instruments to cell preparation, tissue culture, and analysis facilities including fluorescent microscopy and mammalian cell culturing hoods. The department also boasts various advanced instruments such as NMR, UV/Vis spectrophotometers, X-ray equipment, chromatography and mass spectroscopy systems, and fluorimetry and photolysis apparatus, alongside general miscellaneous lab equipment.
2026-02-19 20:57:34
Bio-Rad Laboratories (BIO) reported modest revenue growth of 2.1% but demonstrated strong free cash flow growth of 30.7%. Despite this, the company's valuation appears stretched with a Price-to-Earnings (P/E) ratio of 55.4 and an Enterprise Value to Sales (EV/Sales) of 4.7. Investors should consider the potential for growth to decelerate and how that might impact future returns, especially given the current valuation.
2026-02-17 15:26:57
Bio-Rad's revenue growth recovery is facing uncertainty, pushed back by its 2026 guidance. The company, a leader in life sciences research and clinical diagnostics, relies on a "razor-and-blade" model with consumables accounting for about 70% of sales. Despite a soft market, previous reports indicated the company was on track to meet full-year targets.
2026-02-13 10:57:21
Bio-Rad Laboratories, Inc. has released its annual Form 10-K report for the fiscal year ended December 31, 2025, detailing financial performance, business operations, and strategic initiatives. The company reported net sales of $2,583.2 million, a significant increase in net income to $759.9 million, and continued challenges in the biopharma market. Strategic initiatives include the acquisition of Stilla Technologies and maintaining a strong liquidity position, while significant risks include market competition, supply chain disruptions, and global economic conditions.
2026-02-12 21:57:29
Bio-Rad Laboratories, Inc. (BIO) reported its Q4 revenue at $693.2 million, surpassing the FactSet estimate of $688.8 million. This earnings flash highlights the company's financial performance, specifically its revenue outperforming analyst expectations for the fourth quarter.
2026-02-02 13:28:20
Mawer Investment Management Ltd. significantly reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.9% in Q3, selling 23,640 shares. Despite this reduction, other institutional investors, such as First Eagle Investment Management LLC, increased their holdings, and institutional investors collectively own 65.24% of the company's stock. Analyst ratings for Bio-Rad are mixed, with a consensus "Hold" rating and an average price target of $358.50, although some analysts have upgraded their ratings or price targets.
